A High-Stakes Shift in US Health Policy
In a controversial policy shift that has immediately drawn the ire of federal regulators, the Trump administration and US Health Secretary Robert F. Kennedy Jr. are moving to ease access to popular peptides. According to recent draft policy documents, the administration plans to allow compound pharmacies to make and temporarily sell up to six unapproved peptides, bypassing stringent traditional clearance routes.
FDA Scientists Push Back
The decision has ignited an internal firestorm within the nation's premier health agency. Reports from the Associated Press and other major outlets indicate that Food and Drug Administration (FDA) scientists strongly opposed the move, raising serious safety and efficacy concerns regarding the widespread distribution of unapproved biochemical substances. Critics argue that fast-tracking these compounds without exhaustive clinical trials sets a dangerous precedent for pharmaceutical regulation in the United States.
